Cathay Biotech authorizes its subsidiary for mutual guarantee, with a limit not exceeding 2 billion

Shanghai Cathay Biotech Co., Ltd. announced that in order to meet the development and operational needs of its non-wholly-owned subsidiaries, it authorizes them to provide guarantees when applying for credit and conducting daily operations with other non-wholly-owned subsidiaries. The total balance of guarantees during the authorization period shall not exceed 2 billion yuan, with the actual amount subject to contracts or approvals. As of the announcement date, the total external guarantees of non-wholly-owned subsidiaries amount to 500 million yuan, all of which are inter-subsidiary guarantees, with no overdue or litigation-related guarantees. The main guaranteed parties include Cathay Biomaterials Co., Ltd. and Cathay Biotechnology Co., Ltd., both of which have a debt-to-asset ratio not exceeding 70%. This authorization has been reviewed and approved by the board of directors and does not require shareholder meeting approval. The guarantee risk is controllable, and there is no situation that harms the interests of the company and its shareholders